KDNY News and Press, Chinook Therapeutics Inc Com From 02/22/22

SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4 th Annual Chronic Kid...

SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the ISN World Congress of Nephr...

SEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a ...

SEATTLE, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Charlotte Jones-Burton, M.D., M.S. as ...

Enrollment ongoing in atrasentan pivotal phase 3 ALIGN study in IgAN and phase 2 AFFINITY study in proteinuric glomerular diseases Chinook expects to present data from the IgAN patient cohort of the phase 2 AFFINITY study in the first half of 2022, with data from one o...

Beijing's BeiGene announced its Shanghai STAR Exchange IPO will raise $3.5 billion in gross proceeds for the company, more than the predictions of $3 billion. Suzhou Abogen Biosciences, an mRNA company, raised $300 million to support development of its COVID-19 vaccine and other drug ...

Chinook Therapeutics (NASDAQ:KDNY) has entered into a 50/50 joint venture with an investor syndicate to form SanReno Therapeutics to develop and commercialize kidney disease therapies in China. Frazier Healthcare Partners and Pivotal bioVenture Partners China, as well as existing Chinook inve...

50/50 joint venture with investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China Expands global reach and execution for Chinook’s atrasentan and BION-1301 programs in IgA nephropathy (IgAN) SEATTLE , Nov. 30, 2021 ...

SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced the closing of its upsized underwritten public offering of 9,538,572 shares of its common stock at a price to the public of $14.00 per share, which includes the exercise in full of the under...

Chinook Therapeutics (NASDAQ:KDNY) has priced its upsized underwritten public offering of 7,828,572 shares of its common stock at a price to the public of $14.00/share, for expected gross proceeds of $159.6M. In addition, it is offering pre-funded warrants to purchase 3,571,428 comm...